ES2409033T3 - Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo - Google Patents

Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo Download PDF

Info

Publication number
ES2409033T3
ES2409033T3 ES01935167T ES01935167T ES2409033T3 ES 2409033 T3 ES2409033 T3 ES 2409033T3 ES 01935167 T ES01935167 T ES 01935167T ES 01935167 T ES01935167 T ES 01935167T ES 2409033 T3 ES2409033 T3 ES 2409033T3
Authority
ES
Spain
Prior art keywords
treatment
imidazol
hydroxyethane
minutes
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01935167T
Other languages
English (en)
Spanish (es)
Inventor
John J. Seaman
Bruno Galli
Horst Schran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9891987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2409033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Application granted granted Critical
Publication of ES2409033T3 publication Critical patent/ES2409033T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES01935167T 2000-05-19 2001-05-09 Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo Expired - Lifetime ES2409033T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012209.3A GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds
GB0012209 2000-05-19
PCT/US2001/014886 WO2001089494A2 (en) 2000-05-19 2001-05-09 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases

Publications (1)

Publication Number Publication Date
ES2409033T3 true ES2409033T3 (es) 2013-06-24

Family

ID=9891987

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01935167T Expired - Lifetime ES2409033T3 (es) 2000-05-19 2001-05-09 Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo

Country Status (9)

Country Link
EP (1) EP1286665B1 (enExample)
JP (3) JP2004501104A (enExample)
CN (1) CN100389772C (enExample)
AU (2) AU2001261283B2 (enExample)
BR (1) BR0110913A (enExample)
CA (1) CA2409930C (enExample)
ES (1) ES2409033T3 (enExample)
GB (1) GB0012209D0 (enExample)
WO (1) WO2001089494A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
WO2006062876A2 (en) 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
DK1930414T3 (da) * 2005-09-08 2012-10-22 Medinet Co Ltd Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle
JP5829400B2 (ja) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
CN102000035B (zh) * 2010-10-13 2012-07-25 江苏奥赛康药业股份有限公司 一种供注射用的唑来膦酸组合物及其制备方法
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2519120C1 (ru) * 2012-11-06 2014-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
BE1021270B1 (nl) * 2014-06-17 2015-10-14 Neogen N.V. Zoledronine oplossing
CN105213407B (zh) * 2015-07-01 2018-01-02 南京大学 唑来膦酸用于制备治疗脂肪性肝病的药物的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate

Also Published As

Publication number Publication date
JP2004501104A (ja) 2004-01-15
JP2012162531A (ja) 2012-08-30
EP1286665B1 (en) 2013-04-17
WO2001089494A2 (en) 2001-11-29
EP1286665A2 (en) 2003-03-05
WO2001089494A8 (en) 2003-04-17
GB0012209D0 (en) 2000-07-12
CA2409930A1 (en) 2001-11-29
WO2001089494A3 (en) 2002-05-23
BR0110913A (pt) 2003-12-30
AU6128301A (en) 2001-12-03
CN100389772C (zh) 2008-05-28
CN1481247A (zh) 2004-03-10
CA2409930C (en) 2012-08-28
AU2001261283B2 (en) 2005-01-13
JP2013151553A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
JP2012162531A (ja) 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用
ES2287191T3 (es) Uso de acido zoledronico para el tratamiento del dolor.
RU2238736C2 (ru) Фармацевтическая парентеральная композиция, содержащая бифосфонат
RU2297229C2 (ru) Фармацевтическое применение бисфосфонатов
AU2001261283A1 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
US8324189B2 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
WO2011107646A1 (es) Composición farmacéutica
CA3006954C (en) Stable dosage form of etidronate-cytarabine conjugate, and use thereof
US11045487B2 (en) Pharmaceutical preparation treating bone lesions caused by malignant neoplasms